Joe
06-01-2008, 05:07 PM
<LINK href="/v7jsplib/plwc/css/plwc.css" type=text/css rel=stylesheet> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD noWrap width="100%"><!-- begin header area --><TABLE height=76 cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=top align=left background=/v7jsplib/plwc/images/banner_back_1.jpg>http://www.cancer.net/v7jsplib/plwc/images/PLWCUpper1.jpg (http://www.cancer.net/)http://www.cancer.net/v7jsplib/plwc/images/PlwcUpper2.jpg</TD><TD vAlign=top align=left background=/v7jsplib/plwc/images/banner_back_1.jpg><FORM style="BORDER-RIGHT: 1px; PADDING-RIGHT: 0px; BORDER-TOP: 1px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px" name=FormSearchTop action=/portal/site/patient/menuitem.c1a7f34f8f49af9e16970b106e37a01d/?javax.portlet.tpst=7949ca1cb2fe4f9e16970b106e37a0 1d_ws_MX&javax.portlet.prp_7949ca1cb2fe4f9e16970b106e37a01d _viewID=RESULT_SET_VIEW&javax.portlet.prp_7949ca1cb2fe4f9e16970b106e37a01d _search_engine_id=autonomy&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken method=post><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=style17 vAlign=top align=right>http://www.cancer.net/v7jsplib/plwc/images/PlwcUpper3.jpg
</TD></TR><TR><TD class=style20 vAlign=center noWrap align=right><TABLE cellSpacing=0 cellPadding=4 width=335 border=0><TBODY><TR><TD vAlign=center align=middle><INPUT id=qt maxLength=100 size=35 name=qt> http://www.cancer.net/portal/images/plwc/button_go.gif (javascript: SearchAction();)</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></FORM></TD></TR><TR><TD vAlign=top align=left colSpan=2> </TD></TR></TBODY></TABLE><SCRIPT language=JavaScript type=""> var frmseachtop = document.FormSearchTop; function SearchAction() { frmseachtop.submit(); } </SCRIPT><!-- end header area --></TD></TR></TBODY></TABLE><!--vgn-portal:includeStyle friendlyID="page_controls"/--><TABLE height=240 cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=top align=left width="100%"><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=top><!-- Begin Table: Breadcrumb --><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD>Home (http://www.cancer.net/portal/site/patient) > News and Events (http://www.cancer.net/patient/News+and+Events) > Research and Meetings (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings) > ASCO Annual Meetings (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings) > Breast Cancer (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings/Breast+Cancer)
</TD></TR></TBODY></TABLE><!-- End Table: Breadcrumb --><!--br /--><!--sorted objects -->
Incidence of Heart Failure in Women Receiving Trastuzumab Does Not Increase Over Time
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=body_text>
June 3, 2007
After five years, the risk of congestive heart failure (CHF) associated with adding trastuzumab (Herceptin) to combination chemotherapy for early-stage breast cancer did not increase, according to a phase III clinical trial from the National Surgical Adjuvant Breast and Bowel Project (NSABP). CHF can cause symptoms such as shortness of breath and a reduction in the heart's pumping ability, as measured by the left ventricular ejection fraction (LVEF).
"We are encouraged by these new data showing no additional late heart problems associated with trastuzumab," said lead author Priya Rastogi, MD, Assistant Director of Medical Affairs for the NSABP and Assistant Professor of Medicine at the University of Pittsburgh Cancer Institute in Pennsylvania. "While we still need to check patients closely for side effects to the heart, this is reassuring news for women taking this drug."
Trastuzumab works by blocking the human epidermal growth factor receptor 2 (HER2), which is present in unusually high levels in approximately 20% to 25% of women with breast cancer. Previous studies showed that adding trastuzumab to chemotherapy for women with early-stage HER2-positive breast cancer lowered the risk of the return of breast cancer by 52% after three years compared with chemotherapy alone. One of these studies from the NSABP showed that the occurrence of CHF at three years was 4% for the women taking trastuzumab, compared with 0.8% of women who did not receive trastuzumab.
As part of the NSABP clinical trial, women with HER2-positive breast cancer that had spread to the lymph nodes received either doxorubicin (Adriamycin, Rubex) and cyclophosphamide (Cytoxan, Neosar), followed by paclitaxel (Taxol), or the same treatment plus trastuzumab. The occurrence of CHF was compared between the two groups (1, 850 women in total).
After five years, the occurrence of CHF remained at 4% for the women who received trastuzumab. The researchers also observed an improvement in LVEF over time among women in the trastuzumab group who experienced an initial decline in heart function.
What This Means for Patients
In this study, heart failure occurred in 4% of women with breast cancer who were treated with trastuzumab. Some factors that increased a woman's risk of heart failure included being age 50 or older, a low to normal LVEF, and high blood pressure. Women with breast cancer should talk with their doctors about their risk factors for heart problems to help make appropriate breast cancer treatment decisions.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD></TR><!--tr> <!--td>http://her2support.org/portal/images/misc/spacer.gif <> </tr--></TBODY></TABLE><!--img src = "/portal/templates/template0005/TaXVQeTWVWfZYecUTQedUbRQeeTXaQRd/footer_printable_2.jpg" width = "762" height ="34"--><!--_mlc/breadcrumb=Home/News and Events/Research and Meetings/ASCO Annual Meetings/--><!--_pn=Incidence of Heart Failure in Women Receiving Trastuzumab Does Not Increase Over Time--><!--cname=Breast Cancer--><!-- THE PAGE YOU HAVE VISTED IS : Incidence+of+Heart+Failure+in+Women+Receiving+Tras tuzumab+Does+Not+Increase+Over+Time--><SCRIPT language=javascript> function getCookie(c_name) { if (document.cookie.length>0){ c_start=document.cookie.indexOf(c_name + "=") if (c_start!=-1) { c_start=c_start + c_name.length+1 c_end=document.cookie.indexOf(";",c_start) if (c_end==-1) c_end=document.cookie.length return unescape(document.cookie.substring(c_start,c_end)) } } return "" } </SCRIPT><!--WEBSIDESTORY CODE HBX1.0 (Universal)--><!--COPYRIGHT 1997-2005 WEBSIDESTORY,INC. ALL RIGHTS RESERVED. U.S.PATENT No. 6,393,479B1. MORE INFO:http://websidestory.com/privacy--><SCRIPT language=javascript> var _hbEC=0,_hbE=new Array;function _hbEvent(a,b){b=_hbE[_hbEC++]=new Object();b._N=a;b._C=0;return b;} var hbx=_hbEvent("pv");hbx.vpc="HBX0100u";hbx.gn="ehg-ASCO.HITBOX.COM"; //BEGIN EDITABLE SECTION //CONFIGURATION VARIABLES hbx.acct="DM551220KEFE80EN3";//ACCOUNT NUMBER(S) hbx.pn="Incidence+of+Heart+Failure+in+Women+Receiving+Tras tuzumab+Does+Not+Increase+Over+Time";//PAGE NAME(S) hbx.mlc="Home/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings/Breast+Cancer/Print/";//MULTI-LEVEL CONTENT CATEGORY hbx.pndef="title";//DEFAULT PAGE NAME hbx.ctdef="full";//DEFAULT CONTENT CATEGORY //OPTIONAL PAGE VARIABLES //ACTION SETTINGS hbx.fv="";//FORM VALIDATION MINIMUM ELEMENTS OR SUBMIT FUNCTION NAME hbx.lt="auto";//LINK TRACKING hbx.dlf="n";//DOWNLOAD FILTER hbx.dft="n";//DOWNLOAD FILE NAMING hbx.elf="n";//EXIT LINK FILTER //SEGMENTS AND FUNNELS hbx.seg="";//VISITOR SEGMENTATION hbx.fnl="";//FUNNELS //CAMPAIGNS hbx.cmp="";//CAMPAIGN ID hbx.cmpn="CMP";//CAMPAIGN ID IN QUERY hbx.dcmp="";//DYNAMIC CAMPAIGN ID hbx.dcmpn="DCMP";//DYNAMIC CAMPAIGN ID IN QUERY hbx.dcmpe="";//DYNAMIC CAMPAIGN EXPIRATION hbx.dcmpre="";//DYNAMIC CAMPAIGN RESPONSE EXPIRATION hbx.hra="";//RESPONSE ATTRIBUTE hbx.hqsr="";//RESPONSE ATTRIBUTE IN REFERRAL QUERY hbx.hqsp="HQS";//RESPONSE ATTRIBUTE IN QUERY hbx.hlt="";//LEAD TRACKING hbx.hla="";//LEAD ATTRIBUTE hbx.gp="";//CAMPAIGN GOAL hbx.gpn="";//CAMPAIGN GOAL IN QUERY hbx.hcn="";//CONVERSION ATTRIBUTE hbx.hcv="";//CONVERSION VALUE hbx.cp="null";//LEGACY CAMPAIGN hbx.cpd="";//CAMPAIGN DOMAIN //CUSTOM VARIABLES hbx.ci="";//CUSTOMER ID hbx.hc1="";//CUSTOM 1 hbx.hc2=getCookie("D021");//CUSTOM 2 hbx.hc3="";//CUSTOM 3 hbx.hc4="";//CUSTOM 4 hbx.hrf="";//CUSTOM REFERRER hbx.pec="";//ERROR CODES //INSERT CUSTOM EVENTS //END EDITABLE SECTION //REQUIRED SECTION. CHANGE "YOURSERVER" TO VALID LOCATION ON YOUR WEB SERVER (HTTPS IF FROM SECURE SERVER) </SCRIPT><SCRIPT language=javascript1.1 src="http://www.asco.org/v7jsplib/common/hbe.js" defer></SCRIPT><!--END WEBSIDESTORY CODE-->
</TD></TR><TR><TD class=style20 vAlign=center noWrap align=right><TABLE cellSpacing=0 cellPadding=4 width=335 border=0><TBODY><TR><TD vAlign=center align=middle><INPUT id=qt maxLength=100 size=35 name=qt> http://www.cancer.net/portal/images/plwc/button_go.gif (javascript: SearchAction();)</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></FORM></TD></TR><TR><TD vAlign=top align=left colSpan=2> </TD></TR></TBODY></TABLE><SCRIPT language=JavaScript type=""> var frmseachtop = document.FormSearchTop; function SearchAction() { frmseachtop.submit(); } </SCRIPT><!-- end header area --></TD></TR></TBODY></TABLE><!--vgn-portal:includeStyle friendlyID="page_controls"/--><TABLE height=240 cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=top align=left width="100%"><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=top><!-- Begin Table: Breadcrumb --><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD>Home (http://www.cancer.net/portal/site/patient) > News and Events (http://www.cancer.net/patient/News+and+Events) > Research and Meetings (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings) > ASCO Annual Meetings (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings) > Breast Cancer (http://www.cancer.net/patient/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings/Breast+Cancer)
</TD></TR></TBODY></TABLE><!-- End Table: Breadcrumb --><!--br /--><!--sorted objects -->
Incidence of Heart Failure in Women Receiving Trastuzumab Does Not Increase Over Time
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=body_text>
June 3, 2007
After five years, the risk of congestive heart failure (CHF) associated with adding trastuzumab (Herceptin) to combination chemotherapy for early-stage breast cancer did not increase, according to a phase III clinical trial from the National Surgical Adjuvant Breast and Bowel Project (NSABP). CHF can cause symptoms such as shortness of breath and a reduction in the heart's pumping ability, as measured by the left ventricular ejection fraction (LVEF).
"We are encouraged by these new data showing no additional late heart problems associated with trastuzumab," said lead author Priya Rastogi, MD, Assistant Director of Medical Affairs for the NSABP and Assistant Professor of Medicine at the University of Pittsburgh Cancer Institute in Pennsylvania. "While we still need to check patients closely for side effects to the heart, this is reassuring news for women taking this drug."
Trastuzumab works by blocking the human epidermal growth factor receptor 2 (HER2), which is present in unusually high levels in approximately 20% to 25% of women with breast cancer. Previous studies showed that adding trastuzumab to chemotherapy for women with early-stage HER2-positive breast cancer lowered the risk of the return of breast cancer by 52% after three years compared with chemotherapy alone. One of these studies from the NSABP showed that the occurrence of CHF at three years was 4% for the women taking trastuzumab, compared with 0.8% of women who did not receive trastuzumab.
As part of the NSABP clinical trial, women with HER2-positive breast cancer that had spread to the lymph nodes received either doxorubicin (Adriamycin, Rubex) and cyclophosphamide (Cytoxan, Neosar), followed by paclitaxel (Taxol), or the same treatment plus trastuzumab. The occurrence of CHF was compared between the two groups (1, 850 women in total).
After five years, the occurrence of CHF remained at 4% for the women who received trastuzumab. The researchers also observed an improvement in LVEF over time among women in the trastuzumab group who experienced an initial decline in heart function.
What This Means for Patients
In this study, heart failure occurred in 4% of women with breast cancer who were treated with trastuzumab. Some factors that increased a woman's risk of heart failure included being age 50 or older, a low to normal LVEF, and high blood pressure. Women with breast cancer should talk with their doctors about their risk factors for heart problems to help make appropriate breast cancer treatment decisions.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD></TR><!--tr> <!--td>http://her2support.org/portal/images/misc/spacer.gif <> </tr--></TBODY></TABLE><!--img src = "/portal/templates/template0005/TaXVQeTWVWfZYecUTQedUbRQeeTXaQRd/footer_printable_2.jpg" width = "762" height ="34"--><!--_mlc/breadcrumb=Home/News and Events/Research and Meetings/ASCO Annual Meetings/--><!--_pn=Incidence of Heart Failure in Women Receiving Trastuzumab Does Not Increase Over Time--><!--cname=Breast Cancer--><!-- THE PAGE YOU HAVE VISTED IS : Incidence+of+Heart+Failure+in+Women+Receiving+Tras tuzumab+Does+Not+Increase+Over+Time--><SCRIPT language=javascript> function getCookie(c_name) { if (document.cookie.length>0){ c_start=document.cookie.indexOf(c_name + "=") if (c_start!=-1) { c_start=c_start + c_name.length+1 c_end=document.cookie.indexOf(";",c_start) if (c_end==-1) c_end=document.cookie.length return unescape(document.cookie.substring(c_start,c_end)) } } return "" } </SCRIPT><!--WEBSIDESTORY CODE HBX1.0 (Universal)--><!--COPYRIGHT 1997-2005 WEBSIDESTORY,INC. ALL RIGHTS RESERVED. U.S.PATENT No. 6,393,479B1. MORE INFO:http://websidestory.com/privacy--><SCRIPT language=javascript> var _hbEC=0,_hbE=new Array;function _hbEvent(a,b){b=_hbE[_hbEC++]=new Object();b._N=a;b._C=0;return b;} var hbx=_hbEvent("pv");hbx.vpc="HBX0100u";hbx.gn="ehg-ASCO.HITBOX.COM"; //BEGIN EDITABLE SECTION //CONFIGURATION VARIABLES hbx.acct="DM551220KEFE80EN3";//ACCOUNT NUMBER(S) hbx.pn="Incidence+of+Heart+Failure+in+Women+Receiving+Tras tuzumab+Does+Not+Increase+Over+Time";//PAGE NAME(S) hbx.mlc="Home/News+and+Events/Research+and+Meetings/ASCO+Annual+Meetings/Breast+Cancer/Print/";//MULTI-LEVEL CONTENT CATEGORY hbx.pndef="title";//DEFAULT PAGE NAME hbx.ctdef="full";//DEFAULT CONTENT CATEGORY //OPTIONAL PAGE VARIABLES //ACTION SETTINGS hbx.fv="";//FORM VALIDATION MINIMUM ELEMENTS OR SUBMIT FUNCTION NAME hbx.lt="auto";//LINK TRACKING hbx.dlf="n";//DOWNLOAD FILTER hbx.dft="n";//DOWNLOAD FILE NAMING hbx.elf="n";//EXIT LINK FILTER //SEGMENTS AND FUNNELS hbx.seg="";//VISITOR SEGMENTATION hbx.fnl="";//FUNNELS //CAMPAIGNS hbx.cmp="";//CAMPAIGN ID hbx.cmpn="CMP";//CAMPAIGN ID IN QUERY hbx.dcmp="";//DYNAMIC CAMPAIGN ID hbx.dcmpn="DCMP";//DYNAMIC CAMPAIGN ID IN QUERY hbx.dcmpe="";//DYNAMIC CAMPAIGN EXPIRATION hbx.dcmpre="";//DYNAMIC CAMPAIGN RESPONSE EXPIRATION hbx.hra="";//RESPONSE ATTRIBUTE hbx.hqsr="";//RESPONSE ATTRIBUTE IN REFERRAL QUERY hbx.hqsp="HQS";//RESPONSE ATTRIBUTE IN QUERY hbx.hlt="";//LEAD TRACKING hbx.hla="";//LEAD ATTRIBUTE hbx.gp="";//CAMPAIGN GOAL hbx.gpn="";//CAMPAIGN GOAL IN QUERY hbx.hcn="";//CONVERSION ATTRIBUTE hbx.hcv="";//CONVERSION VALUE hbx.cp="null";//LEGACY CAMPAIGN hbx.cpd="";//CAMPAIGN DOMAIN //CUSTOM VARIABLES hbx.ci="";//CUSTOMER ID hbx.hc1="";//CUSTOM 1 hbx.hc2=getCookie("D021");//CUSTOM 2 hbx.hc3="";//CUSTOM 3 hbx.hc4="";//CUSTOM 4 hbx.hrf="";//CUSTOM REFERRER hbx.pec="";//ERROR CODES //INSERT CUSTOM EVENTS //END EDITABLE SECTION //REQUIRED SECTION. CHANGE "YOURSERVER" TO VALID LOCATION ON YOUR WEB SERVER (HTTPS IF FROM SECURE SERVER) </SCRIPT><SCRIPT language=javascript1.1 src="http://www.asco.org/v7jsplib/common/hbe.js" defer></SCRIPT><!--END WEBSIDESTORY CODE-->